LONDON, ONTARIO February 25, 2020 -- OB Pharmaceuticals announces the addition of two new members to its Scientific and Clinical Advisory, Dr. Peter Carlen and Dr. Pavel Klein. Dr. Carlen is Professor in Medicine (Neurology), Physiology, and the Institute of Biomaterials and Biomedical Engineering at the University of Toronto. He has over 300 peer-reviewed biomedical publications and 6 patents. His main research interests are mechanisms, pharmacology, and control of neural synchrony and entrainment in epilepsy, sudden unexpected death in epilepsy (SUDEP), brain state classification, gap junctional communication, and using human cerebral organoids to study epilepsy. He is also an active neurological clinician at the University Health Network (Toronto Western Hospital) with a practice focused mainly on patients with epilepsy. Dr. Pavel Klein is Director of the Mid-Atlantic Epilepsy and Sleep Center, Clinical Professor of Neurology at George Washington University. He was former Instructor in Neurology at Harvard Medical School and Director of the Epilepsy Program of the Clinical Neurophysiology Laboratory and of the Neuroendocrine Unit at the Georgetown University Hospital. Dr. Klein’s clinical research includes novel treatments of epilepsy, dietary treatments of epilepsy in adults, prevention of epilepsy after traumatic brain injury, the effect of sex and stress hormones on epilepsy, and women with epilepsy. "Drs. Carlen and Klein will provide invaluable guidance going forward as we move through late preclinical and into the regulatory process and clinical development," remarked Dr. Larry Mahan, CEO, "We are extremely pleased they have come onboard."
About OB Pharmaceuticals
OB Pharmaceuticals is an early stage biopharmaceutical company dedicated to improving the lives of individuals through the development of first-in-class therapeutics for more effective prevention and management of epilepsy and other related seizure disorders.